Price T Rowe Associates Inc. MD Reduces Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Price T Rowe Associates Inc. MD lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,319,385 shares of the biopharmaceutical company's stock after selling 132,448 shares during the quarter. Price T Rowe Associates Inc. MD owned 2.57% of Alnylam Pharmaceuticals worth $781,085,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Allworth Financial LP increased its stake in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock valued at $140,000 after buying an additional 38 shares during the period. Nixon Peabody Trust Co. increased its position in Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock valued at $540,000 after purchasing an additional 43 shares during the period. IFP Advisors Inc increased its position in Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 47 shares during the period. Nwam LLC increased its position in Alnylam Pharmaceuticals by 5.8% during the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock valued at $213,000 after purchasing an additional 50 shares during the period. Finally, National Bank of Canada FI increased its position in Alnylam Pharmaceuticals by 9.0% during the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company's stock valued at $157,000 after purchasing an additional 55 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares of the company's stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 7,392 shares of company stock worth $1,875,627. 1.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Stifel Nicolaus increased their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research report on Monday, March 31st. Finally, JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $280.00 to $328.00 in a report on Monday, March 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $315.58.

Alnylam Pharmaceuticals Stock Up 1.5 %

NASDAQ:ALNY traded up $3.78 during trading hours on Tuesday, hitting $258.63. 295,820 shares of the company traded hands, compared to its average volume of 875,611. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm's 50-day simple moving average is $247.46 and its 200-day simple moving average is $255.63. Alnylam Pharmaceuticals, Inc. has a one year low of $143.50 and a one year high of $304.39. The company has a market cap of $33.64 billion, a PE ratio of -119.59 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.